Literature DB >> 18925427

Effects of humoral immunity and calreticulin overexpression on postoperative course in breast cancer.

Aleksandra Erić1, Zorica Juranić, Zorka Milovanović, Ivan Marković, Momcilo Inić, Nevenka Stanojević-Bakić, Vesna Vojinović-Golubović.   

Abstract

The aim was to investigate whether the humoral immunity and overexpression of calreticulin in tumor tissue determined before surgery, correlate with incidence of metastases in breast cancer patients within two years after operation. Before operation, their humoral immunity and overexpression of caleticulin and Her-2/neu in tumor tissue were analyzed by immunohystochemistry. In 23 patients with metastases in regionally lymph nodes, seven had Her-2/neu overexpression. Among those seven patients, three developed distant metastasis (two women one year and in one woman two years after surgery) and all of them showed the presence of stromal IgG immunoreactivity and overexpression of calreticulin in their tumors tissue. Preliminary data showed that serum IgG immunoreactivity to tumor stroma in combination with overexpression of calreticulin in tumor cells correlate with postoperative appearance of metastases, particularly in the group of patients with Her-2/neu overexpressed tumors and metastases in axillary lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18925427     DOI: 10.1007/s12253-008-9112-2

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  9 in total

1.  Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process.

Authors:  Emilio Barbera-Guillem; Julie K Nyhus; Chris C Wolford; Chad R Friece; James W Sampsel
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

2.  Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines.

Authors:  Eiko Hayashi; Yasuhiro Kuramitsu; Futoshi Okada; Masanori Fujimoto; Xiulian Zhang; Masanobu Kobayashi; Norio Iizuka; Yoshiya Ueyama; Kazuyuki Nakamura
Journal:  Proteomics       Date:  2005-03       Impact factor: 3.984

3.  The urokinase/urokinase receptor system mediates the IgG immune complex-induced inflammation in lung.

Authors:  Nelli Shushakova; Gabriele Eden; Marc Dangers; Joerg Zwirner; Jan Menne; Faikah Gueler; Friedrich C Luft; Hermann Haller; Inna Dumler
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

4.  The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.

Authors: 
Journal:  Oncologist       Date:  1998

5.  Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement.

Authors:  Marco Colleoni; Nicole Rotmensz; Giulia Peruzzotti; Patrick Maisonneuve; Giovanni Mazzarol; Giancarlo Pruneri; Alberto Luini; Mattia Intra; Paolo Veronesi; Viviana Galimberti; Rosalba Torrisi; Anna Cardillo; Aron Goldhirsch; Giuseppe Viale
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

6.  Perforin lytic activity is controlled by calreticulin.

Authors:  S A Fraser; R Karimi; M Michalak; D Hudig
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

7.  Impaired cytolytic activity in calreticulin-deficient CTLs.

Authors:  Simonetta Sipione; Catherine Ewen; Irene Shostak; Marek Michalak; R Chris Bleackley
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

8.  Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma.

Authors:  Joachim Dissemond; Michael Busch; Thomas Kothen; Janet Mörs; Tatjana K Weimann; Anette Lindeke; Manfred Goos; Stephan N Wagner
Journal:  Cancer Lett       Date:  2004-01-20       Impact factor: 8.679

9.  Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression.

Authors:  M J Scanlan; I Gout; C M Gordon; B Williamson; E Stockert; A O Gure; D Jäger; Y T Chen; A Mackay; M J O'Hare; L J Old
Journal:  Cancer Immun       Date:  2001-03-30
  9 in total
  14 in total

1.  Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer.

Authors:  Rui-Qing Peng; Ying-Bo Chen; Ya Ding; Rong Zhang; Xing Zhang; Xing-Juan Yu; Zhi-Wei Zhou; Yi-Xin Zeng; Xiao-Shi Zhang
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

Review 2.  Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation.

Authors:  A D Garg; E Romano; N Rufo; P Agostinis
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

3.  Calreticulin is a novel independent prognostic factor for oral squamous cell carcinoma.

Authors:  Koji Harada; Takanori Takenawa; Tarannum Ferdous; Yasuhiro Kuramitsu; Yoshiya Ueyama
Journal:  Oncol Lett       Date:  2017-04-20       Impact factor: 2.967

4.  Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients.

Authors:  Jitka Fucikova; Iva Truxova; Michal Hensler; Etienne Becht; Lenka Kasikova; Irena Moserova; Sarka Vosahlikova; Jana Klouckova; Sarah E Church; Isabelle Cremer; Oliver Kepp; Guido Kroemer; Lorenzo Galluzzi; Cyril Salek; Radek Spisek
Journal:  Blood       Date:  2016-11-01       Impact factor: 22.113

Review 5.  Proteomic Research on the Antitumor Properties of Medicinal Mushrooms.

Authors:  Boris Jakopovic; Nada Oršolić; Ivan Jakopovich
Journal:  Molecules       Date:  2021-11-05       Impact factor: 4.411

Review 6.  Calreticulin and cancer.

Authors:  Mohammadreza Zamanian; Abhi Veerakumarasivam; Syahril Abdullah; Rozita Rosli
Journal:  Pathol Oncol Res       Date:  2013-02-08       Impact factor: 3.201

7.  Calreticulin is a B cell molecular target in some gastrointestinal malignancies.

Authors:  A Pekáriková; D Sánchez; L Palová-Jelínková; M Simsová; Z Benes; I Hoffmanová; P Drastich; I Janatková; T Mothes; H Tlaskalová-Hogenová; L Tucková
Journal:  Clin Exp Immunol       Date:  2009-12-17       Impact factor: 4.330

8.  Comparison of protein expression profiles of different stages of lymph nodes metastasis in breast cancer.

Authors:  Hui-Hua Lee; Chu-Ai Lim; Yew-Teik Cheong; Manjit Singh; Lay-Harn Gam
Journal:  Int J Biol Sci       Date:  2012-02-20       Impact factor: 6.580

Review 9.  Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer.

Authors:  Jitka Fucikova; Irena Moserova; Linda Urbanova; Lucillia Bezu; Oliver Kepp; Isabelle Cremer; Cyril Salek; Pavel Strnad; Guido Kroemer; Lorenzo Galluzzi; Radek Spisek
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

Review 10.  Calreticulin and cancer.

Authors:  Jitka Fucikova; Radek Spisek; Guido Kroemer; Lorenzo Galluzzi
Journal:  Cell Res       Date:  2020-07-30       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.